Intech Investment Management LLC Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Intech Investment Management LLC bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the third quarter, Holdings Channel reports. The institutional investor bought 18,914 shares of the company’s stock, valued at approximately $63,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. MAI Capital Management increased its position in Trevi Therapeutics by 0.7% in the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after acquiring an additional 8,789 shares during the period. Oppenheimer & Co. Inc. increased its holdings in shares of Trevi Therapeutics by 34.7% in the third quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock valued at $274,000 after purchasing an additional 21,128 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Trevi Therapeutics during the third quarter worth approximately $409,000. SG Americas Securities LLC acquired a new stake in shares of Trevi Therapeutics during the third quarter worth $78,000. Finally, The Manufacturers Life Insurance Company grew its position in Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after buying an additional 11,450 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $2.76 on Monday. Trevi Therapeutics, Inc. has a 1-year low of $1.07 and a 1-year high of $4.00. The company has a market capitalization of $212.16 million, a price-to-earnings ratio of -6.27 and a beta of 0.96. The business has a 50-day moving average of $2.99 and a 200-day moving average of $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the firm posted ($0.08) earnings per share. Research analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TRVI. B. Riley restated a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Raymond James began coverage on Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, December 4th. Finally, Leerink Partners began coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.13.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.